Titles

  • Co-Director CHUM Microbiome Centre
  • Research member at the Montreal Cancer Institute
  • Assistant Professor, Department of Hematology & Oncology, Université de Montréal
  • Clinician Scientist, Cancer Axis, CHUM Research Center

Mission

  • We are a translational oncology lab focused on developing and advancing novel microbiome-based therapeutics in oncology.

Laboratory Team

  • Gabryella Pinheiro PhD, Postdoctoral Research Fellow
  • Kyoung Su Kim, PhD, Postdoctoral Research Fellow
  • Sebastian Hunter MSc, Staff Computational Biologist and Bioinformatician
  • Alysé Filin BSc, Research Assistant
  • Diana Rusu, MSc student
  • Sreya Duttagupta, PhD candidate (co-supervision with Dr. Bertrand Routy MD PhD)
  • Claudia Sayed BSc, Melanoma Biobank Research Coordinator
  • Edmond Rafie, MD, Resident

Recent Publications

  1. Immune-related colitis is associated with fecal microbial dysbiosis and can be mitigated by fecal microbiota transplantation
  2. Intratumoral Escherichia Is Associated with Improved Survival to Immune Checkpoint Inhibitors in Lung Cancer 
  3. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
  4. The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development

Pubmed Page

Full Bibliography

Email address for application

Arielle.elkrief.med@ssss.gouv.qc.ca

Biography

Dr. Arielle Elkrief MD, FRCPC is a clinician-scientist FRSQ J1 (ranked #1), Assistant Professor in the Department of Oncology at the Centre hospitalier de l’Université de Montréal (CHUM), and Co-Director of the CHUM Microbiome Centre. She was recruited to the CRCHUM in 2023 and directs a translational oncology lab focused on developing and advancing novel microbiome-based therapeutics in oncology . She leads microbiome-centered clinical trials studying microbiome interventions such as fecal microbiota transplantation (FMT), prebiotics, and diet in combination with immune checkpoint inhibitors. In addition, she contributed to establishing the negative impact of antibiotics on immunotherapy activity in patients with cancer. Her computational biology team uses integrated approaches in metagenomics and culturomics to understand the mechanism driving microbiome interventions in oncology.

She was recently awarded the American Society of Clinical Oncology Young Investigator Award and the Society of Immunotherapy of Cancer-Melanoma Research Alliance Women in Melanoma Award. She has published over 90 papers in peer-reviewed journals including the Journal of Clinical Oncology, Nature Medicine, Journal of Thoracic Oncology, Annals of Oncology and Nature Reviews Drug Discovery.